FDA Determines A “Class Effect” Is In Play For All NSAIDs
This article was originally published in The Tan Sheet
Executive Summary
An FDA decision to request revised safety labeling changes to OTC NSAIDs enables manufacturers to continue positioning the drugs as safer alternatives to their prescription counterparts, which will carry "black box" warnings going forward
You may also be interested in...
Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
The nonselective NSAIDs naproxen and ibuprofen appear neither to increase nor decrease the risk of cardiovascular events, according to a Journal of the American Medical Association data review published online Sept. 12
Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
The nonselective NSAIDs naproxen and ibuprofen appear neither to increase nor decrease the risk of cardiovascular events, according to a Journal of the American Medical Association data review published online Sept. 12
Traditional NSAIDs Do Not Raise Cardiovascular Risk – JAMA Review
The nonselective NSAIDs naproxen and ibuprofen appear neither to increase nor decrease the risk of cardiovascular events, according to a Journal of the American Medical Association data review published online Sept. 12